When systematically administered, anti‐VEGF agents have been reported to cause hypertension, myocardial infarction, thromboembolic events and stroke (Ranpura et al., 2010; Skillings et al., 2005; Tlemsani et al., 2016). Here, VEGFA is linked to hypertensive disorder.